Why Asthma Clinical Trials Matter in the UK
Asthma is not one condition but a collection of subtypes, each driven by different underlying inflammatory processes. This is why the same brown inhaler that keeps one person symptom-free may leave another still wheezing and reaching for their reliever multiple times a day. Research in the UK has been at the forefront of unpicking these differences. The ABRA trial, led by King's College London and sponsored by the University of Oxford, tested whether a biologic injection called benralizumab could outperform standard steroid tablets during acute asthma exacerbations. The findings, published in The Lancet Respiratory Medicine, showed that patients receiving the injection had a fourfold reduction in treatment failure compared to those on prednisolone alone. This kind of work, conducted within NHS hospitals, demonstrates how UK trials directly translate into better care pathways.
The UK clinical research landscape benefits from the NHS infrastructure, meaning trials can draw on real-world patient populations rather than highly selected groups. The REMISSION UK study, which involved over 400 patients across NHS sites, examined how people with severe asthma respond to biologic treatments over time. It is precisely this type of observational research that helps clinicians understand which patients are most likely to achieve remission, a concept that was barely discussed in asthma care a decade ago.
Types of Asthma Trials Currently Recruiting in the UK
Asthma trials vary widely in what they test and who they need. Some investigate entirely new molecules; others look at whether existing drugs can be used in new ways. The TezEx study, running at Guy's Severe Asthma Centre in London, is examining the inflammatory profile of exacerbations in patients receiving tezepelumab, a biologic that targets thymic stromal lymphopoietin (TSLP). Because TSLP sits upstream of multiple inflammatory pathways, the trial aims to understand whether tezepelumab can reduce both type 2 and non-type 2 driven attacks, a question that matters for the substantial minority of patients whose asthma does not fit the classic allergic pattern.
Phase III trials, such as the SWIFT and ANCHOR programmes that led to the UK approval of depemokimab (Exdensur) in late 2025, test whether a treatment is effective and safe in large groups. Depemokimab is notable for being the first ultra-long-acting biologic requiring only twice-yearly dosing, a practical advantage for patients who find frequent hospital visits burdensome. Phase IV studies, by contrast, look at how treatments perform in everyday clinical practice once they have been approved. The REMISSION UK study falls into this category.
A simplified breakdown of the main trial types relevant to asthma patients in the UK is shown below.
| Trial Type | What It Tests | Typical Duration | Who It May Suit | Key Considerations |
|---|
| Early-phase (Phase I/II) | Safety, dosing, and preliminary efficacy of a new drug | Weeks to months | Patients with few remaining treatment options | Higher uncertainty; closer monitoring required |
| Late-phase (Phase III) | Efficacy and safety against standard care or placebo | 6 months to 2 years | Patients with specific asthma subtypes | More data available on the drug by this stage |
| Observational (Phase IV) | Real-world effectiveness of approved treatments | Varies | Patients already on a biologic | No experimental intervention; routine care continues |
| Device and digital studies | New inhaler designs, smart monitors, or app-based self-management | Weeks to months | Broad range of asthma severities | Lower medical risk; often less invasive |
Eligibility and the Referral Pathway
Each trial has its own eligibility criteria, but certain patterns hold across most UK asthma studies. Researchers typically look for patients whose asthma remains uncontrolled despite being on medium-to-high-dose inhaled corticosteroids plus a second controller. A common threshold is a history of two or more exacerbations requiring oral corticosteroids in the preceding twelve months. Blood eosinophil counts are frequently used as a biomarker, and many biologic trials require a count above a specified level, often 150 or 300 cells per microlitre.
The route into a trial usually begins with a conversation. Patients can approach their GP or asthma specialist nurse and ask whether any recruiting studies might be appropriate. The NHS website hosts the Be Part of Research portal, which allows anyone to search for asthma trials by location and register their interest. Charities like Asthma + Lung UK also maintain listings of active studies. Some patients find trials through their hospital consultant directly, particularly those attending severe asthma clinics, where research teams are often embedded within the clinical service.
Speaking with a GP before applying is advisable. They can help clarify whether a patient's current medication regimen is already optimised and whether taking part in a study might interfere with existing care. It is worth noting that no referral is strictly required to express interest in a trial, and initial contact with a research team carries no obligation.
What Participation Actually Looks Like
The experience of being in an asthma trial varies, but most follow a similar rhythm. After an initial screening visit, where blood tests, lung function measurements, and a detailed medical history are taken, eligible participants enter the active phase of the study. This might involve receiving an injection every few weeks, using a new inhaler device, or keeping a daily symptom diary. Elaine Wal, a 61-year-old former nurse from Bradford, became the first European participant in the TIDE trial and described making visits to the research centre every four weeks while recording her peak flow each morning and evening. She had already taken part in two previous asthma studies and said she was motivated by the chance to help others as well as herself.
The commitment is not trivial. Some trials require regular hospital visits over a year or more. Others involve additional procedures such as induced sputum tests or bronchoscopies. Travel costs are often reimbursed, and most NHS-based studies do not charge participants anything. The trial team provides all medication and monitoring at no cost to the patient. This is an important point: patients in UK clinical trials do not pay for the investigational treatment or any associated care.
One concern that arises frequently is the possibility of receiving a placebo. In many respiratory trials, the control arm receives standard care plus a placebo, meaning no patient goes entirely untreated. The trial team will explain the randomisation process during the consent stage, and patients can withdraw at any time without affecting their usual NHS care.
Risks, Safeguards, and What to Ask
Every clinical trial in the UK must be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and an independent research ethics committee before it can begin. These bodies scrutinise the study design, the information provided to patients, and the safeguards in place. The research team is required to report any serious adverse events, and trials can be halted early if safety concerns emerge.
Practical questions to ask before joining include: How many visits are required and how long is each one? Will travel expenses be covered? What happens if the treatment works, and what happens when the trial ends? Can the treatment be continued afterwards through the NHS? The answer to the last question depends on whether the drug has been approved by NICE for routine use, which is not always the case at the time a trial concludes.
The UK has a strong tradition of patient involvement in research. Many trials now include patient advisory groups to help shape the study design and ensure that the questions being asked matter to the people living with the condition. This shift towards co-production, rather than research done to patients, has been quietly reshaping how asthma studies are conducted across the country. For anyone considering a trial, the first step is simply to look up what is recruiting nearby and ask.
研究の知恵